Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
56,785,960
-
Share change
-
+810,851
-
Total reported value
-
$1,022,155,424
-
Put/Call ratio
-
21%
-
Price per share
-
$18.00
-
Number of holders
-
126
-
Value change
-
+$15,328,009
-
Number of buys
-
71
-
Number of sells
-
57
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q3 2021
As of 30 Sep 2021,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
126 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,785,960 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, VR Adviser, LLC, Rock Springs Capital Management LP, BlackRock Inc., Foresite Capital Management IV, LLC, VANGUARD GROUP INC, COMMODORE CAPITAL LP, RENAISSANCE TECHNOLOGIES LLC, Holocene Advisors, LP, and Foresite Capital Management III, LLC.
This page lists
126
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.